Latest & greatest articles for valsartan

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on valsartan or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on valsartan and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for valsartan

21. Sacubitril/valsartan - Addendum to Commission A15-60

Sacubitril/valsartan - Addendum to Commission A15-60 1 Translation of addendum A16-29 Sacubitril/Valsartan – Addendum zum Auftrag A15-60 (Version 1.0; Status: 25 May 2016). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum 25 May 2016 1.0 Commission: A16-29 Version: Status: IQWiG Reports – Commission No. A16-29 Sacubitril/valsartan – Addendum (...) to Commission A15-60 1 Addendum A16-29 Version 1.0 Sacubitril/valsartan (Addendum to Commission A15-60) 25 May 2016 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Sacubitril/valsartan – Addendum to Commission A15-60 Commissioning agency: Federal Joint Committee Commission awarded on: 10 May 2016 Internal Commission No.: A16-29 Address of publisher: Institut für Qualität und Wirtschaftlichkeit im

2017 Institute for Quality and Efficiency in Healthcare (IQWiG)

22. Sacubitril + valsartan (Entresto) in chronic heart failure. Favourable results in highly selected patients

Sacubitril + valsartan (Entresto) in chronic heart failure. Favourable results in highly selected patients Prescrire IN ENGLISH - Spotlight ''Sacubitril + valsartan (Entresto°) in chronic heart failure. Favourable results in highly selected patients'', 1 February 2017 {1} {1} {1} | | > > > Sacubitril + valsartan (Entresto°) in chronic heart failure. Favourable results in highly selected patients Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |    (...) |   |   |   |   |   |   |   |  Spotlight Sacubitril + valsartan (Entresto°) in chronic heart failure. Favourable results in highly selected patients FEATURED REVIEW Replacing an ACE inhibitor or an ARB with the high-dose sacubitril + valsartan combination should be envisaged with care, and solely for heart failure patients comparable to those included in the only available trial. Most chronic heart failure patients should continue to use

2017 Prescrire

23. ENTRESTO - Sacubitril/valsartan (as sacubitril valsartan sodium hydrate complex)

ENTRESTO - Sacubitril/valsartan (as sacubitril valsartan sodium hydrate complex) Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity for SBDs written

2017 Health Canada - Drug and Health Product Register

24. Sacubitril/Valsartan: Getting to the Heart of This Novel Therapy

Sacubitril/Valsartan: Getting to the Heart of This Novel Therapy Tools for Practice is proudly sponsored by the Alberta College of Family Physicians (ACFP). ACFP is a provincial, professional voluntary organization, representing more than 4,500 family physicians, family medicine residents, and medical students in Alberta. Established over sixty years ago, the ACFP strives for excellence in family practice through advocacy, continuing medical education and primary care research. www.acfp.ca July (...) 10, 2017 Sacubitril/Valsartan: Getting to the Heart of This Novel Therapy Clinical Question: Is sacubitril/valsartan (Entresto®) effective for systolic heart failure (HF)? Bottom Line: Based on one randomized controlled trial (RCT), for every 36 patients with heart failure switched from ACE inhibitors to sacubitril/valsartan, one fewer will die and one fewer will be admitted for heart failure over 27 months. Beta-blockers and aldosterone antagonists should be offered first and continued

2017 Tools for Practice

25. Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial. (PubMed)

Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial. Consensus guidelines recommend the use of mineralocorticoid receptor antagonists (MRAs) for selected patients with symptomatic heart failure and reduced ejection fraction (HFrEF) to reduce morbidity and mortality; however, the use of MRAs in combination with other inhibitors of the renin (...) -angiotensin-aldosterone system increases the risk of hyperkalemia.To determine whether the risk of hyperkalemia associated with use of MRAs for patients with HFrEF is reduced by sacubitril/valsartan in comparison with enalapril.The PARADIGM-HF (Prospective Comparison of ARNI With an ACE-Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure) trial randomly assigned 8399 patients with chronic HF, New York Heart Association class II to IV symptoms, and a left ventricular EF of 40

Full Text available with Trip Pro

2016 JAMA cardiology

26. Sacubitril/valsartan - Benefit assessment

Sacubitril/valsartan - Benefit assessment Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Sacubitril/Valsartan – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 30 March 2016). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A15-60 Sacubitril/valsartan – Benefit assessment according to §35a Social (...) Code Book V 1 Extract of dossier assessment A15-60 Version 1.0 Sacubitril/valsartan – Benefit assessment acc. to §35a Social Code Book V 30 March 2016 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Sacubitril/valsartan – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission awarded on: 23 December 2015 Internal Commission No.: A15-60

2016 Institute for Quality and Efficiency in Healthcare (IQWiG)

27. Cost-Effectiveness of Sacubitril-Valsartan in Patients With Heart Failure With Reduced Ejection Fraction. (PubMed)

Cost-Effectiveness of Sacubitril-Valsartan in Patients With Heart Failure With Reduced Ejection Fraction. Sacubitril-valsartan therapy reduces cardiovascular mortality compared with enalapril therapy in patients with heart failure with reduced ejection fraction.To evaluate the cost-effectiveness of sacubitril-valsartan versus angiotensin-converting enzyme inhibitor therapy in patients with chronic heart failure.Markov decision model.Clinical trials, observational analyses, reimbursement data (...) from the Centers for Medicare & Medicaid Services, drug pricing databases, and Centers for Disease Control and Prevention life tables.Patients at an average age of 64 years, New York Heart Association (NYHA) class II to IV heart failure, and left ventricular ejection fraction of 0.40 or less.Lifetime.Societal.Treatment with sacubitril-valsartan or lisinopril.Life-years, quality-adjusted life-years (QALYs), costs, heart failure hospitalizations, and incremental cost-effectiveness ratios.The

2016 Annals of Internal Medicine

28. Real-life Effectiveness and Safety of Amlodipine/Valsartan Single-pill Combination in Patients with Hypertension in Egypt: Results from the EXCITE Study (PubMed)

Real-life Effectiveness and Safety of Amlodipine/Valsartan Single-pill Combination in Patients with Hypertension in Egypt: Results from the EXCITE Study EXCITE (clinical experience of amlodipine and valsartan in hypertension) evaluated the real-world effectiveness and safety of single-pill combinations (SPCs) of amlodipine/valsartan (Aml/Val) and amlodipine/valsartan/hydrochlorothiazide (Aml/Val/HCTZ) in patients with hypertension from the Middle East and Asia.The objective of this study

Full Text available with Trip Pro

2016 Drugs - real world outcomes

29. [Sacubitril/valsartan: addendum to commission A15-60]

[Sacubitril/valsartan: addendum to commission A15-60] Sacubitril/Valsartan: addendum zum auftrag A15-60; auftrag A16-29 [Sacubitril/valsartan: addendum to commission A15-60] Sacubitril/Valsartan: addendum zum auftrag A15-60; auftrag A16-29 [Sacubitril/valsartan: addendum to commission A15-60] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation (...) of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Sacubitril/Valsartan: addendum zum auftrag A15-60; auftrag A16-29. [Sacubitril/valsartan: addendum to commission A15-60] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 394. 2016 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Humans; Tetrazoles; Valine; Valsartan Language Published

2016 Health Technology Assessment (HTA) Database.

30. [Sacubitril/valsartan - benefit assessment]

[Sacubitril/valsartan - benefit assessment] Sacubitril/valsartan: nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A15-60 [Sacubitril/valsartan - benefit assessment according to §35a Social Code Book V] Sacubitril/valsartan: nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A15-60 [Sacubitril/valsartan - benefit assessment according to §35a Social Code Book V] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record (...) of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Sacubitril/valsartan: nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A15-60. [Sacubitril/valsartan - benefit assessment according to §35a Social Code Book V] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 379. 2016

2016 Health Technology Assessment (HTA) Database.

31. Neparvis (sacubitril / valsartan) - heart failure

Neparvis (sacubitril / valsartan) - heart failure 1 April 2016 EMA/255018/2016 Committee for Medicinal Products for Human Use (CHMP) Assessment Report Neparvis International non-proprietary name: sacubitril / valsartan Procedure No. EMEA/H/C/004343/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 (...) CLCZ696B2314 (also known as PARADIGM-HF) was designed to accomplish this purpose. LCZ696 (sacubitril/valsartan, Neparvis) is a novel therapy proposed for treatment of heart failure (HF) (New York Heart Association (NYHA) class II-IV) in patients with systolic dysfunction (reduced ejection fraction, HFrEF). Following oral administration, LCZ696 dissociates into valsartan and the pro-drug sacubitril (also known as AHU377, a new molecular entity), which is further metabolized to the neprilysin inhibitor

2016 European Medicines Agency - EPARs

32. Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction

Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction Sacubitril valsartan for treating Sacubitril valsartan for treating symptomatic chronic heart failure with symptomatic chronic heart failure with reduced ejection fr reduced ejection fraction action T echnology appraisal guidance Published: 27 April 2016 nice.org.uk/guidance/ta388 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice (...) to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction (TA388) © NICE 2018. All rights reserved. Subject to Notice of rights (https

2016 National Institute for Health and Clinical Excellence - Technology Appraisals

33. Effect of 8-Week Combination Therapy with an Extended-Release α1-Blocker (Bunazosin or Doxazosin) in Inadequate Responders to an Angiotensin II Antagonist (Valsartan) in Patients with Stage 1 or 2 Essential Hypertension. (PubMed)

Effect of 8-Week Combination Therapy with an Extended-Release α1-Blocker (Bunazosin or Doxazosin) in Inadequate Responders to an Angiotensin II Antagonist (Valsartan) in Patients with Stage 1 or 2 Essential Hypertension. Given the favorable impact of α1-blockers on lipid and glucose metabolism, this study was designed to compare the efficacy of two extended-release α1-blockers (bunazosin and doxazosin) as an add-on treatment in subjects with stage 1 or 2 essential hypertension which (...) was inadequately controlled by valsartan 80 mg/day.After a 5-week treatment of valsartan monotherapy, subjects with inadequately controlled hypertension were randomized to receive either extended-release bunazosin (n = 47) or doxazosin (n = 46) after breakfast for 8 weeks. Office sitting blood pressure (BP), 24-hour ambulatory BP, and metabolic profiles were measured at baseline, start of study drug, and study end.In the intention-to-treat population (n = 93), the average daily doses of bunazosin

2016 Zhonghua Minguo xin zang xue hui za zhi = Acta Cardiologica Sinica

34. Amlodipine / Valsartan Mylan - hypertension

Amlodipine / Valsartan Mylan - hypertension 28 January 2016 EMA/CHMP/182030/2016 Committee for Medicinal Products for Human Use (CHMP) Assessment report Amlodipine/Valsartan Mylan International non-proprietary name: amlodipine / valsartan Procedure No. EMEA/H/C/004037/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone (...) /National Formulary UV Ultraviolet light Assessment report EMA/CHMP/182030/2016 Page 4/31 1. Background information on the procedure 1.1. Submission of the dossier The applicant MYLAN S.A.S. submitted on 20 January 2015 an application for Marketing Authorisation to the European Medicines Agency (EMA) for Amlodipine/Valsartan Mylan, through the centralised procedure under Article 3 (3) of Regulation (EC) No. 726/2004 – ‘Generic of a Centrally authorised product’. The eligibility to the centralised

2016 European Medicines Agency - EPARs

35. PARADIGM?HF: Valsartan 160mg po BID + Sacubitril (=LCZ696) versus Enalapril 10mg po BID in Heart Failure

PARADIGM?HF: Valsartan 160mg po BID + Sacubitril (=LCZ696) versus Enalapril 10mg po BID in Heart Failure RXFILES PRELIMINARY TRIAL SUMMARY LYNETTE KOSAR JAN 7 TH , 2015 – WWW.RXFILES.CA Page 1 of 3 PARADIGM-HF: Valsartan 160mg po BID + Sacubitril (=LCZ696) versus Enalapril 10mg po BID in HF 1 Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality & morbidity in HF BOTTOM LINE ? In PARADIGM-HF, clinically stable patients with heart failure (HF) (NYHA class I 5%, class (...) : LCZ696 375±71mg (=valsartan 300±57mg/day), Enalapril 18.9±3.4mg - MEAN SBP AT 8 MONTHS: LCZ696 3.2±0.4mmHg lower (p<0.001), but the authors stated this was not the reason for benefit when it was analyzed as a time-dependent covariate STRENGTHS, LIMITATIONS, & UNCERTAINTIES STRENGTHS: ? Important clinical endpoints (e.g. cardiovascular death, HF hospitalizations) with blinded adjudication of outcomes. ? Only 20 patients lost to follow-up (0.13%). LIMITATIONS: ? No Phase II studies have been conducted

2016 RxFiles

36. LCZ696 (Sacubitril/ Valsartan) ENTRESTO Summary and Practical Tips

LCZ696 (Sacubitril/ Valsartan) ENTRESTO Summary and Practical Tips November 2015 LCZ696 (Sacubitril/Valsartan), Entresto TM Summary and Practical Tips Mechanism of action: sacubitril is a neprilysin (endopeptidase) inhibitor: ?vasodilatory peptides ? ?sodium loss, ?hypertrophy/remodeling. Combination with an ARB is necessary as inhibition of neprilysin leads to activation of the renin angiotensin aldosterone system (RAAS). Indication: • Health Canada Indication 1 : heart failure with reduced (...) ejection fraction (HFrEF), NYHA class II-III, in combination with other heart failure (HF) therapies in place of an ACEI or ARB • CCS HF 2014 Guidelines 2 : mild-moderate HF, left ventricular ejection fraction (LVEF) 5.2 mmol/L • History of angioedema Dosing: • Tablet: film-coated, unscored containing both sacubitril and valsartan (dose is sum of agents) • Strengths: 50 mg (24/26mg; white), 100 mg (49/51mg; yellow), 200 mg (97/103mg; pink) o Note: different valsartan salts; Entresto TM valsartan 103mg

2016 RxFiles

37. Estimating the Long-Term Treatment Benefits of Sacubitril-Valsartan. (PubMed)

Estimating the Long-Term Treatment Benefits of Sacubitril-Valsartan. 26630151 2015 12 22 2015 12 03 1533-4406 373 23 2015 Dec 03 The New England journal of medicine N. Engl. J. Med. Estimating the Long-Term Treatment Benefits of Sacubitril-Valsartan. 2289-90 10.1056/NEJMc1509753 Claggett Brian B Brigham and Women's Hospital, Boston, MA. Packer Milton M McMurray John J V JJ Swedberg Karl K Rouleau Jean J Zile Michael R MR Jhund Pardeep P Lefkowitz Martin M Shi Victor V Solomon Scott D SD (...) PARADIGM-HF Investigators eng Letter United States N Engl J Med 0255562 0028-4793 0 Aminobutyrates 0 Angiotensin Receptor Antagonists 0 Drug Combinations 0 LCZ 696 0 Tetrazoles 80M03YXJ7I Valsartan AIM IM Aged Aged, 80 and over Aminobutyrates therapeutic use Angiotensin Receptor Antagonists therapeutic use Cause of Death Drug Combinations Heart Failure drug therapy mortality Humans Kaplan-Meier Estimate Life Expectancy Middle Aged Tetrazoles therapeutic use Valsartan therapeutic use 2015 12 3 6 0 2015

2015 NEJM

38. Sacubitril/valsartan (TBC)

Sacubitril/valsartan (TBC) Sacubitril/valsartan | CADTH.ca Find the information you need Sacubitril/valsartan Sacubitril/valsartan Last Updated: August 4, 2015 Result type: Reports Project Number: SR0447-000 Product Line: Generic Name: Sacubitril/valsartan Brand Name: Entresto Manufacturer: Novartis Pharmaceuticals Canada Inc. Indications: Heart failure, NYHA class II or III Submission Type: New Project Status: Complete Date Recommendation Issued: March 18, 2016 Recommendation Type: List

2015 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

39. Sacubitril/valsartan (TBC)

Sacubitril/valsartan (TBC) Sacubitril/valsartan | CADTH.ca Find the information you need Sacubitril/valsartan Sacubitril/valsartan Last Updated: August 4, 2015 Result type: Reports Project Number: SR0447-000 Product Line: Generic Name: Sacubitril/valsartan Brand Name: Entresto Manufacturer: Novartis Pharmaceuticals Canada Inc. Indications: Heart failure, NYHA class II or III Submission Type: New Project Status: Complete Date Recommendation Issued: March 18, 2016 Recommendation Type: List

2015 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

40. Sacubitril/valsartan (TBC)

Sacubitril/valsartan (TBC) Sacubitril/valsartan | CADTH.ca Find the information you need Sacubitril/valsartan Sacubitril/valsartan Last Updated: August 4, 2015 Result type: Reports Project Number: SR0447-000 Product Line: Generic Name: Sacubitril/valsartan Brand Name: Entresto Manufacturer: Novartis Pharmaceuticals Canada Inc. Indications: Heart failure, NYHA class II or III Submission Type: New Project Status: Complete Date Recommendation Issued: March 18, 2016 Recommendation Type: List

2015 Canadian Agency for Drugs and Technologies in Health - Common Drug Review